Pharmaceutical perspectives of cancer therapeutics

Yi Lu, Ram I. Mahato

Research output: Book/ReportBook

11 Citations (Scopus)

Abstract

Pharmaceutical Perspectives of Cancer Therapeutics presents a comprehensive yet easy-to-follow review of the principles, current progress and state-of-the-art of cancer therapeutics. The complexity of cancer demands an integrated understanding from both cancer biology and pharmaceutical dosage forms and drug delivery in order to warrant a successful therapeutic regimen. This book combines and merges the knowledge from these two aspects. Internationally acclaimed experts with a multi-disciplinary background, including scientists and clinicians from both academia and industries have contributed to this book to bridge the following areas between basic research and clinical application, pharmaceutical drug development processes and regulatory issues, drug design and delivery, laboratory and translational experimentation, marketing and postmarketing surveillance. Main features of the book: Anticancer drug development and regulatory processes. Strategies to suppress tumor angiogenesis and metastasis, overcome mu ti-drug resistance in cancer, target telomerase and apoptosis pathways. Therapeutic approaches to employ monoclonal antibody and cancer vaccines. Introduction of new concepts such as cancer stem cells and new technologies such as nanobiotechnology, RNA interference, microRNA, and cancer cell gene profiling. Use of lipids, polymers and peptides for drug delivery and targeting to cancer cells or specific organs. Utilization of bioimaging and HIF-1 knockout animal models in cancer study. Clinical trials designs and principles.

Original languageEnglish (US)
PublisherSpringer US
Number of pages693
ISBN (Print)9781441901309
DOIs
StatePublished - Dec 1 2009

Fingerprint

Pharmaceutical Preparations
Neoplasms
Drug delivery
Therapeutics
Nanobiotechnology
Cells
Cancer Vaccines
Telomerase
Dosage Forms
Neoplastic Stem Cells
Stem cells
MicroRNAs
Neoplasm Genes
Drug Design
Drug Delivery Systems
RNA Interference
Marketing
Tumors
Drug Resistance
Polymers

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Pharmaceutical perspectives of cancer therapeutics. / Lu, Yi; Mahato, Ram I.

Springer US, 2009. 693 p.

Research output: Book/ReportBook

Lu, Yi ; Mahato, Ram I. / Pharmaceutical perspectives of cancer therapeutics. Springer US, 2009. 693 p.
@book{5aecdd299a5b432b8b73b042dafcff6c,
title = "Pharmaceutical perspectives of cancer therapeutics",
abstract = "Pharmaceutical Perspectives of Cancer Therapeutics presents a comprehensive yet easy-to-follow review of the principles, current progress and state-of-the-art of cancer therapeutics. The complexity of cancer demands an integrated understanding from both cancer biology and pharmaceutical dosage forms and drug delivery in order to warrant a successful therapeutic regimen. This book combines and merges the knowledge from these two aspects. Internationally acclaimed experts with a multi-disciplinary background, including scientists and clinicians from both academia and industries have contributed to this book to bridge the following areas between basic research and clinical application, pharmaceutical drug development processes and regulatory issues, drug design and delivery, laboratory and translational experimentation, marketing and postmarketing surveillance. Main features of the book: Anticancer drug development and regulatory processes. Strategies to suppress tumor angiogenesis and metastasis, overcome mu ti-drug resistance in cancer, target telomerase and apoptosis pathways. Therapeutic approaches to employ monoclonal antibody and cancer vaccines. Introduction of new concepts such as cancer stem cells and new technologies such as nanobiotechnology, RNA interference, microRNA, and cancer cell gene profiling. Use of lipids, polymers and peptides for drug delivery and targeting to cancer cells or specific organs. Utilization of bioimaging and HIF-1 knockout animal models in cancer study. Clinical trials designs and principles.",
author = "Yi Lu and Mahato, {Ram I.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/978-1-4419-0131-6",
language = "English (US)",
isbn = "9781441901309",
publisher = "Springer US",
address = "United States",

}

TY - BOOK

T1 - Pharmaceutical perspectives of cancer therapeutics

AU - Lu, Yi

AU - Mahato, Ram I.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Pharmaceutical Perspectives of Cancer Therapeutics presents a comprehensive yet easy-to-follow review of the principles, current progress and state-of-the-art of cancer therapeutics. The complexity of cancer demands an integrated understanding from both cancer biology and pharmaceutical dosage forms and drug delivery in order to warrant a successful therapeutic regimen. This book combines and merges the knowledge from these two aspects. Internationally acclaimed experts with a multi-disciplinary background, including scientists and clinicians from both academia and industries have contributed to this book to bridge the following areas between basic research and clinical application, pharmaceutical drug development processes and regulatory issues, drug design and delivery, laboratory and translational experimentation, marketing and postmarketing surveillance. Main features of the book: Anticancer drug development and regulatory processes. Strategies to suppress tumor angiogenesis and metastasis, overcome mu ti-drug resistance in cancer, target telomerase and apoptosis pathways. Therapeutic approaches to employ monoclonal antibody and cancer vaccines. Introduction of new concepts such as cancer stem cells and new technologies such as nanobiotechnology, RNA interference, microRNA, and cancer cell gene profiling. Use of lipids, polymers and peptides for drug delivery and targeting to cancer cells or specific organs. Utilization of bioimaging and HIF-1 knockout animal models in cancer study. Clinical trials designs and principles.

AB - Pharmaceutical Perspectives of Cancer Therapeutics presents a comprehensive yet easy-to-follow review of the principles, current progress and state-of-the-art of cancer therapeutics. The complexity of cancer demands an integrated understanding from both cancer biology and pharmaceutical dosage forms and drug delivery in order to warrant a successful therapeutic regimen. This book combines and merges the knowledge from these two aspects. Internationally acclaimed experts with a multi-disciplinary background, including scientists and clinicians from both academia and industries have contributed to this book to bridge the following areas between basic research and clinical application, pharmaceutical drug development processes and regulatory issues, drug design and delivery, laboratory and translational experimentation, marketing and postmarketing surveillance. Main features of the book: Anticancer drug development and regulatory processes. Strategies to suppress tumor angiogenesis and metastasis, overcome mu ti-drug resistance in cancer, target telomerase and apoptosis pathways. Therapeutic approaches to employ monoclonal antibody and cancer vaccines. Introduction of new concepts such as cancer stem cells and new technologies such as nanobiotechnology, RNA interference, microRNA, and cancer cell gene profiling. Use of lipids, polymers and peptides for drug delivery and targeting to cancer cells or specific organs. Utilization of bioimaging and HIF-1 knockout animal models in cancer study. Clinical trials designs and principles.

UR - http://www.scopus.com/inward/record.url?scp=84900201808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900201808&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0131-6

DO - 10.1007/978-1-4419-0131-6

M3 - Book

SN - 9781441901309

BT - Pharmaceutical perspectives of cancer therapeutics

PB - Springer US

ER -